Medical Director
Resume:
Peter G. Polos, MD, PhD, DAASM, FCCP
New Jersey Governor, American College of Chest Physicians
Basking Ridge, NJ
*******@*****.***
BACKGROUND: I have had a career spanning academic and clinical medicine, basic research, pharmaceutical medical and scientific affairs, CRO experience and private consulting. This has given me the opportunity to function in many roles, including senior executive leadership. I have developed and lead multi-functional teams addressing a spectrum of patient and administrative issues such as patient safety, trial design, scientific and clinical strategy, and health economics and outcomes research. I have lead teams to evaluate in-licensing and business development opportunities. I have an extensive opinion leader network from which I am able to access a wealth of experience and opinion.
I have maintained an active teaching and clinical practice. This has allowed me to remain current and board certified in pulmonary medicine and sleep medicine and to continue to be aware of the challenges faced by physicians and hospitals with respect to the practice of medicine, ethical and social issues, managed care and reimbursement. I have presented scientific data in over 25 countries. I am also involved at the policy level within the American College of Chest Physicians.
I am Associate Professor at Seton Hall University through which I teach at the only sleep fellowship program in New Jersey at JFK Medical Center, Sleep Center. There I have teaching and clinicla responsibilities and direct a varied research program. I have worked closely with a major manufacturere of devices for the treatment of sleep apnea. Finally, I practice part time pulmonary and critical care medicine with the Summit Medical Group,.
EDUCATION
1986 Doctor of Medicine
Louisiana State University Medical Center School of Medicine
New Orleans, Louisiana, USA
1981 Doctor of Philosophy, Microbiology and Immunology
Louisiana State University Medical Center School of Graduate Studies
New Orleans, Louisiana, USA
1978 Master of Science, Microbiology and Immunology
School of Medicine
New Orleans, Louisiana, USA
1975 Bachelor of Arts, Biological Sciences
Rutgers University
New Brunswick, New Jersey, USA
MEDICAL TRAINING
1989 to 1991 Fellowship, Pulmonary, Critical Care, Sleep Medicine
Division of Pulmonary and Critical Care Medicine
Medical University of South Carolina
Charleston, SC, USA
1986 to 1988 Internal Medicine Internship and Residency
Chief Medical Resident
New York Infirmary – Beekman Downtown Hospital
New York, NY, USA
BOARD CERTIFICATION
2000, 2011 Diplomate
American Academy Sleep Medicine
1994, 2010 Diplomate
American Board of Internal Medicine, Pulmonary Diseases
1991 Diplomate
American Board of Internal Medicine, Internal Medicine
PROFESSIONAL EXPERIENCE
2012 to present Founder of Global Clinical Consulting, LLC
Basking Ridge, NJ,
• Provide domestic and global strategic, scientific, marketing, clinical expertise and medical monitoring
• Therapeutic areas have included: respiratory medicine, sleep medicine, allergic disease, inflammation, cardiovascular disease, renal
diseases
• Develop scientific leadership strategy in a multi-specialty approach utilizing HEOR, regulatory, clinical and marketing resources
• Utilize extensive global opinion leader network in US, EU, LA and Asia as needed
2008 to 2012 Group Leader, Respiratory and Infectious Disease
i3 Research
Basking Ridge, NJ, USA
Responsibilities included medical/clinical components of the following product/service areas: clinical research and data analysis, health outcomes, study feasibility, study design and protocol development, reporting and publishing, consulting, and overall service delivery
Therapeutic areas included respiratory, allergic, infectious, inflammatory, renal, gastroenterology and dermatologic diseases
Lead and participated in the process of peer review, and generation of abstracts, articles, work-shops, books, chapters etc.
Responsible for clinical components of various product/services, study design and conduct, in particular study start up (including kick-off meeting support, investigator meetings, site selection, specialized scales and CRF design, and IRB interactions) for phases II-IV
Spokesperson for the company in regional and national pharmaceutical and healthcare therapeutic forums
Clinical lead to marketing and business development teams, providing medical affairs input
2007 to 2008 Global Director for Scientific Affairs, Respiratory Franchise
Merck & Co., Inc.
Whitehouse Station, New Jersey, USA
:
Co-chair of the World Wide Respiratory Advisory Board, developing the agenda, formulating clinical strategies and collaborating with board members for continued research opportunities
Chairman of the Investigator Initiated Studies Program; oversaw the review process for externally submitted research proposals
Chairman of multi-disciplinary team to devsie scientific leadersip engagement strategy and franchise clinical strategy
2003 to 2007 Senior Medical Director, Respiratory Franchise
Merck & Co., Inc
Whitehouse Station, New Jersey, USA
2001 to 2003 Medical Director, Respiratory Franchise
Merck & Co., Inc
Whitehouse Station, New Jersey, USA
Medical lead to markeitng and commercial teams, providing scientific and clincial iput to comercial issues
Organized, presented at or chaired speakers’ forums and symposia in over 25 countries, focusing on clinical and health outcomes aspects of respiratory disorders
Represented the respiratory franchise at expert input forums and US based Global Therapeutic Expert Forums.
Designed adult and pediatric clinical trials, lead investigator meetings and served as the medical monitor to trials that have enrolled over 5000 patients.
Member of the product development team to develop balanced scientific and commercial initiatives
Member of sub-team responsible for the review and analysis of opportunities, including in-licensing opportunities, acquisitions, and device development
Member of regulatory review team providing medical and scientific input and representing clinical interests at regulatory/FDA meetings
Initiated a screening program for sleep disorders within headquarters and have designed a world-wide screening and treatment program for fatigue in the work place.
2003 to present Associate Professor of Sleep Medicine
JFK Sleep Disorders Center, Seton Hall UniversitySchool of Health and Medical Sciences Program
Seton Hall University School of Graduate Medical Education
Edison, NJ, USA
2003 to present Attending Staff, Pulmonary & Critical Care Medicine
Overlook Hospital, Summit Medical Group
Summit, NJ, USA
Director
SMG Sleep Laboratory
Summit, NJ USA
2007 to present Instructor, School of Medicine, Clinical Department of General Practice and Pulmonary Care
University of Aberdeen
Aberdeen, UK
2011 to present Associate Professor of Health Sciences
Seton Hall University,
West Orange, NJ, USA
1995 to 2001 Medical Director, Pulmonary & Critical Care Medicine
Morton Physicians Associates / Morton Hospital and Medical Center
Medical Director
Morton Hospital Sleep Disorders Laboratory
Medical Director, Pulmonary Health and Rehabilitation
Morton Hospital, Taunton, MA, USA
Medical Director
Digitrace Center for Sleep Medicine
Hyannis, MA, USA
Medical Director
Massasoit Community College Sleep Technologist Program
Brockton, MA, USA
1991 to 1995 Medical Director, Pulmonary & Critical Care Medicine
Medical Director, Sleep Disorder Laboratory
Medical Director, Pulmonary Rehabilitation
Falmouth Hospital, Falmouth, MA, USA
PROFESSIONAL ASSOCIATIONS
New Jersey Governor for the American College of Chest Physicians
American College of Chest Physicians
American Thoracic Society
American Academy of Sleep Medicine
American Academy of Pharmaceutical Physicians
SCIENTIFIC ADVISORY BOARDS
Merck and Co. Health Economics and Outcomes Research for New Products
DelMedica Instruments, Scientific Advisory Board
Juvenile Diabetes Research Foundation
HONORS
Merck Strategic Excellence for Marketing and Medical Affairs, 2004, 2007, 2008
Merck Franchise of the Year for Singulair 2006
Fellow, American College of Chest Physicians, 1996
Chief Medical Resident, New York Infirmary-Beekman Downtown Hospital, 1988-1989
ASSM Workshop on Clinical Trials in Obstructive Sleep Apnea, 1999
PUBLICATIONS - MANUSCRIPTS
1 .Asthma outcomes and cost effectiveness with extrafine beclomethasone and fluticasone
G. Colice,, R. Martin, E. Isrea, N. Roche, N. Barnes, A. Burden, P.G. Polos, P. Dorinsky, L.Hillyer, A.J. Lee, A. Chisholm, J von Ziegenweidt, F. Barion, D. Price
Submitted: Annals Internal Medicine
2. Effect of Montelukast for Treatment of Asthma in Cigarette Smokers
David Price, Todor A. Popov, Leif Bjermer3, Susan Lu, Romana Petrovic, Kristel Vandormael, Anish Mehta, Jolanta D. Strus, Peter G. Polos, George Philip
Submitted: American J Respiratory and Critical Care Medicine
3. The Effect of Montelukast or Salmeterol Added to Inhaled Fluticasone on Exercise-Induced Bronchoconstriction in Children 6 to 14 Years of Age.
Fogel R, Rosario N, Aristizabal G, Loeys T, Gaile S, Noonan GP, Smugar SS, Polos, PG
Annals of Allergy, Asthma and Immunology, 26 April 2010
4. The efficacy of montelukast during the allergy season in pediatric
patients with persistent asthma and seasonal aeroallergen sensitivity
Nikos Papadopoulos, MD, George Phillip, MD, Hilde Giezek, PhD, Molly Watkins, Steven S. Smugar, Peter G. Polos, MD, PhD
Journal Asthma, 01 May 2009
5. Additional benefit of montelukast on lung function in asthma patients with allergic rhinitis: Analysis from the, COMPACT Trial David B. Price, MD, Arlene Swern, PhD, Carol A. Tozzi, PhD, George Philip, MD, Peter G. Polos, MD, PhD
Allergy, June 2006 - Vol. 61 Issue 6: 653-789
6. Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the improving asthma control trial.
Bousquet J, Gaugris S, Sazonov Kocevar V, Zhang Q, Yin, DD, Polos PG, Bjermer Clin Exp Allergy 2005; 35:723-727
7. Oral montelukast sodium versus inhaled fluticasone propionate in adults with mild persistent asthma J. Bousquet, J. Menten, C.A. Tozzi, P.G. Polos
J. Appl Research, 2005; 3: 402-405
8. Montelukast, compared with fluticasone, for control of asthma among 6-14 year old patients with mild asthma: The MOSAIC Study. M. Luz Garcia Garcia, U. Whan, L. Gilles, A.Swern, C.A. Tozzi, P.G. Polos.
Pediatrics, 2005; 116: 360-366
9. Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the improving asthma control trial.
J. Bousquet, S. Gaugris, V. Sazonov Kocevar, Q. Zhang,D.D. Yin, P.G. Polos, L. Bjermer.
Clin Exp Allergy, 2005;35:723-727
10. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbations in adults: one year, double blind, randomized, comparative trial L. Bjermer, H. Bisgaard, J. Bousquet, L. M. Fabbri, A. P.Greening, T. Haahtela, S.T. Holgate, C. Picado, J. Menten, S. B. Dass, J. Leff, P. G. Polos
British Medical Journal, Oct 2003; 327:891-896
11. Respiratory Failure in a 30 year-old Spelunker Peter G. Polos, M.D., Ph.D.
Chest, 1998, 113(4): 1125-1126
12. A Review of Thoracic Vascular Anatomy and Complications of Central Catheter Placement Peter G. Polos, M.D., Ph.D., S.A. Sahn, M.D.
J. Critical Care Illness, 1993, 8:660-674
13. Pulmonary Hypertension and HIV Infection: Two Reports and a Review of the Literature Peter G. Polos, M.D., Ph.D., D. Wolf, M.D., R. Harley, M.D., S.A. Sahn, M.D. Chest, 1991, 101:474-478
14. Arterial or Venous? You Make the Call Peter G. Polos, M.D., Ph.D., F. Rinaldo, M.D.,M. Bhalla, M.D., S.A. Sahn, M.D. Chest, 1992, 101:591
15. Complication of Central Venous Center Insertion: Artery Embolism Peter G. Polos, M.D., Ph.D., S.A. Sahn, M.D. J. Critical Care Medicine, 1991, 19(3):3-5
16. Cocaine and Asthma: A Fatal Combination A.N. Rao M.D., Peter G. Polos, M.D., Ph.D. NY State Medical Journal, 1990, 90:511-512
17. Acute Mercury Poisoning and Mercurial Pneumonitis from Gold Ore Purification
M.L. Levin, M.D., J. Jacobs, M.D., Peter G. Polos, M.D., Ph.D. Chest, 1987, 94:554-556
18. Independent Effects of Phytohemagglutinin on Cell Fusion and Attachment Peter G. Polos, W.R. Gallaher, Ph.D. Virology, 1981, 119:268-275
19. A Quantitative Assay for Cytolysis Induced by Newcastle Disease Virus Peter G. Polos, W.R. Gallaher, Ph.D. J. General Virology, 1981, 52:259-265
20. Insensitivity of a Ricin-Resistant Mutant of Chinese Hamster Ovary Cells to Fusion Induced by Newcastle Disease Virus Peter G. Polos, W.R. Gallaher, Ph.D.
J. Virology, 1979, 30:69-75
PUBLICATIONS – ABSTRACTS
1. Treatment of smoking asthmatics with fluticasone and montelukast shows a bimodal distribution of response and no significant difference between the two therapies
D. Price, T. A. Popov, L. Bjermer, S. Lu, R. Petrovic, K, Vandormael, A. Mehta,
J. Strus, P.r G. Polos, J. Fish, G. Philip
Asian Pacific Society of Respirology, November 2011
2. Composite asthma control measures in real-life studies
D..Price, R. Martin, G. Colice, P. Dorinsky, A. Chisholm, J von Ziegenweidt, A. Burden, P. G. Polos, L.Hillyer, N. Roche
European Respiratory Society, Amsterdam, September 2011
3. A randomized, placebo-controlled study of asthmatic smokers treated with
montelukast or fluticasone
D. Price, T. Popov, A. Mehta, P.G. Polos, G. Philip
European Respiratory Society, Amsterdam, September 2011
4. Increasing asthma therapy as extrafine hydrofluoroalkane beclomethasone or fluticasone: a real-world comparative effectiveness study from the United States
RJ Martin, G Colice, N Barnes, E Israel, N Roche, A Lee, D Price, P Dorinsky, P Polos, A Burden, J von Ziegenweidt, A Chisholm
Submitted to American Thoracic Society Denver 2011
5. Real-world effectiveness of extrafine hydrofluoroalkane beclomethasone and fluticasone: United Kingdom and United State data compared
G Colice, RJ Martin, N Barnes, E Israel, N Roche, A Lee, D Price, P Dorinsky, P Polos, A Burden, J von Ziegenweidt, A Chisholm
Submitted to America Thoracic Society, Denver 2011
6. Comparative effectiveness of extrafine hydrofluoroalkane beclomethasone and fluticasone in asthma management: a real-world observational study from the United States
D Price, P Dorinsky, P Polos, A Burden, J von Ziegenweidt, A Chisholm
Submitted to American Academy of Asthma, Allergy and Immunology,
San Francisco, 2011
7. Central Apnea in REM Sleep in a Patient with TBI and Long Term Opioid Therapy.
Peter G. Polos, Michael Seyffert, Besher Kabak, Irving Smith, Shusanth Batt, Chaman Preet Chalal, Eli S., Divya Gupta, Sudhansu Chokroverty
2010 American College of Chest Physicians, Vancouver CN
8. The Effect of Sleep Time Related Information and Communication Technology (STRICT) on Sleep Patterns and Daytime Functioning in Children and Young Adults: A Pilot Study Seyffert M, Bhat S, Smith I, Kabak B, Sillari J, Gupta D, Polos PG, DeBari VA, Neiman ES, Chokroverty S . 2010 Associated Professional Sleep Societies San Antonio, TX
9. Right Versus Left Lateral Head Position During Supine Sleep Causing Variation in Respiratory Events in Patients with Sleep Disordered Breathing Kabak B, Riar SS, Bhat S, Smith I, Seyffert M, Gupta D, Polos PG, Chokroverty S. 2010 Associated Professional Sleep Societies San Antonio, TX
10. The Effect of Sleep Time Related Information and Communication Technology (STRICT) on Sleep Patterns and Daytime Functioning in Children and Young Adults: A Pilot Study Polos PG, Bhat S, Smith I, Kabak B, Sillari J, Gupta D, Seyffert M, DeBari VA, Neiman ES, Chokroverty S. 2010 European Respiratory Society, Barcelona Spain
11. A Comparison of Clinical Profiles, Medication Use, and Symptomology in Asthma Patients Prescribed Low/Moderate Dose Fluticasone Propionate/Salmeterol or Moderate/High Dose Fluticasione Propionate Polos, PG 2010 International Scocety for Pharmacoeconomics and Outcome Research, Atlanta GA
12. Attenuation of Exercise-Induced Bronchoconstriction with Montelukast or Salmeterol in Children Fogel R, Rosario N, Aristizabal G, Loeys T, Gaile S, Noonan GP, Smugar SS, Polos, PG 2009 European Respiratory Society Vienna, Austria
13. Effect of Montelukast or Salmeterol on Response to Albuterol in Children with Exercise-Induced Bronchoconstriction Fogel R, Aristizabal G, Rosario N, Loeys T, Gaile S, Noonan GP, Smugar SS, Polos PG 2009 European Respiratory Society
Vienna, Austria
14. Effect of montelukast on asthma exacerbation rates in pediatric patients with or without prior oral steroid use - a posthoc analysis of the Previa trial of viral-associated asthma H Bisgaard, AS Swern, SB Dass, PG Polos 2007 American Thoracic Society San Francisco, CA
15. Increased risk of asthma attacks and emergency visits among asthma
patients with allergic rhinitis: a subgroup analysis of the IMPACT trial Bousquet J, Sazonov Kocevar V, Zhang Q, YinDD, Polos PG, 2004 European Academy of Allergy, Asthma and Immunology (EAACI), Amsterdam, The Netherlands (June 2004)
16. Health care resource utilization following addition of montelukast or
Salmeterol to fluticasone in patients with inadequately controlled asthma (IMPACT trial)
Bjermer L, Zhang Q, Sazonov Kocevar V, Yin D, Polos P.G. Eur Resp J 2004; 24(Suppl. 48): 127S (P857)
17. Healthcare resource use following addition of montelukast to budesonide compared to doubling the dose of budesonide in patients with inadequately controlled asthma (COMPACT trial) Price D, Zhang Q, Sazonov Kocevar V, Polos P, Yin D. Eur Resp J 2004; 24(Suppl. 48): 126S (P855)
18. Increased Resource Use among Asthmatic Children with Concomitant Allergic Rhinitis: A Subgroup Analysis of the MOSAIC Trial. Sazonov Kocevar V, Garcia Garcia ML, Zhang Q, Polos, PG. Proceedings of the American Thoracic Society (ATS) May 2005; Vol. 2: A699
19. Efficacy of Montelukast in prevention of viral-induced asthma (The PREVIA Study)
H. Bisgaard, L.Giles, J.Menten, C.Tozzi, P.G.Polos World Asthma Organization, Bangkok, 2004
20. Effect of Montelukast on Eosinophilic Inflammation In Asthma: Analysis of COMPACT and IMPACT Trials P. G. Polos, T. Haahtela, P. Rytila, L. Bjermer, D. Price American Thoracic Society. Seattle 2003.
21. Montelukast or Salmeterol Added to Fluticasone in Uncontrolled Asthma: A Subgroup Analysis of the IMPACT Trial L. Bjermer, H. Bisgaard, J. Bousquet, L. Fabbri, A. Greening, T. Haahtela, S.T. Holgate, C. Picado, J. Menten, J. Leff, P. G. Polos American College of Chest Physicians. Denver 2002
22. Additional Benefit of Montelukast for Asthma in Patients with Both Asthma and Allergic Rhinitis: Aalysis from the COMPACT Trial. D. B. Price, M.D., A.S. Swern, C.A. Tozzi, G. Phillip, M.D., and P.G.Polos, M.D., PhD. World Allergy Organization Congress-XVIII ICACI 2003, p.29
32. Montelukast and the Prevention of Viral Induced Asthma (The PREVIA Study)
H. Bisgaard, M.D., S. Zielen, M.D., P. G. Polos, M.D.,PhD. European Respiratory Society, 2003
LETTERS
1. Letter to the Editor. Further assessment of the equivalence of anti-leukotrienes and ICS. BMJ. June 2003.
2. Letter to the Editor: Montelukast is an effective monotherapy for mild asthma and for asthma with co-morbid allergic rhinitis. Primary Care Respiratory Journal. May 2006
Contact this candidate